

# 2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

## Treatment

No Injectable Lesions

Injectable Lesions

Prior - PD(L)1

Max 2 Prior Therapies

Amenable to Paired Biopsies

ROR2 Positive

Max 4 Prior Therapies in R/M Setting

**ECOG-ACRIN-EA3202**  
Phase II/III  
[Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab](#)  
Following Progression on Immune Checkpoint Inhibition in Recurrent / Metastatic Head & Neck Cancers

PI: Khan  
Sponsor: ECOG-ACRIN

**ENT0100**  
Phase I  
Multicenter Open Label  
First-in-Human ABBV-CLS-579 Alone and in Combination in Locally Advanced or Metastatic Tumors

PI: Colevas  
Sponsor: AbbVie Inc.

**ENT0088**  
Phase II  
[Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma](#)

Safety Run-in 2 / Phase 2 Cohort 3  
PI: Colevas  
Sponsor: Gilead Sciences, Inc.

**ENT0109**  
Open-Label Multicenter Dose-Escalation Phase I/III Study of INBRX-105 & INBRX-105 in Combo w/ Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

PI: Colevas  
Sponsor: Inhibrx, Inc.

**ENT0108**  
Phase II  
Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients w/ Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

PI: Colevas  
Sponsor: BioAtla, Inc.

**ENT0105**  
Phase I/II Study of SRF114 in Patients With Advanced Solid Tumors

PI: Colevas  
Sponsor: Surface Oncology, Inc.

**ENT0064**  
Phase 1b  
[Ad/PNP-F-araAMP + Co-Admin of Fludarabine Phosphate in Recurrent Local Head and Neck Cancer](#)

PI: Colevas  
Sponsor: PNP Therapeutics

### KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Trial Posting

Enrollment on Hold

Extension Study

Immunotherapy